Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 02/25 02:20:08 pm
88.675 USD   -4.79%
09:36aABBVIE : Form 8.3 -
DJ
02/24ABBVIE : Form 8.3 -
DJ
02/24ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/18/2020 02/19/2020 02/20/2020 02/21/2020 02/24/2020 Date
93.61(c) 94.14(c) 94.23(c) 94.96(c) 93.14(c) Last
9 406 845 6 349 082 5 446 168 6 678 156 10 705 075 Volume
-0.47% +0.57% +0.10% +0.77% -1.92% Change
More quotes
Financials (USD)
Sales 2020 35 984 M
EBIT 2020 17 356 M
Net income 2020 10 791 M
Debt 2020 24 609 M
Yield 2020 5,14%
Sales 2021 38 675 M
EBIT 2021 18 990 M
Net income 2021 12 059 M
Debt 2021 19 008 M
Yield 2021 5,58%
P/E ratio 2020 10,3x
P/E ratio 2021 9,47x
EV / Sales2020 4,51x
EV / Sales2021 4,05x
Capitalization 138 B
More Financials
Company
AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with... 
Sector
Pharmaceuticals
Calendar
02/25 | 10:30amPresentation
More about the company
Surperformance© ratings of AbbVie Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC.
09:36aABBVIE : Form 8.3 -
DJ
02/24ABBVIE : Form 8.3 -
DJ
02/24ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/24ABBVIE : Announces Extension of Expiration Date for Exchange Offers for Allergan..
PR
02/21ABBVIE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/21ABBVIE : Form 8.3 -
DJ
02/20ABBVIE : Declares Quarterly Dividend
PR
02/20ABBVIE : Form 8.3 - Abbvie Inc.
DJ
02/19ABBVIE : Form 8.3 - Abbvie Inc
DJ
02/19ABBVIE : to Present at the Cowen 40th Annual Health Care Conference
PR
02/18Monteverde & Associates PC Launches an Investigation of the Board of Director..
PR
02/18ABBVIE : Form 8.3 -
DJ
02/18Gilead's Coronavirus Drug Trial Slowed Due to Lack of Eligible Recruits
DJ
02/17ALLERGAN : Form 8.3 -
DJ
02/17ABBVIE : Form 8.3 -
DJ
More news
News in other languages on ABBVIE INC.
02/10Aktien New York Ausblick: US-Börse nach Gewinnmitnahmen zunächst auf Standby
02/10ALLERGAN : consensus battu au 4e trimestre
02/09Coronavirus und die Börsen
02/07Les valeurs à suivre aujourd'hui à Wall Street Vendredi 7 février 2020
02/07ABBVIE : bat le consensus
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Sector news : Pharmaceuticals - NEC
10:35aDAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
09:39aALLERGAN : Form 8.3 -
DJ
09:03aAPPLE : J&J Opens Enrollment for 'Heartline' Study in Collaboration With Apple
DJ
08:43aSPRING BANK PHARMACEUTICALS : in Clinical Collaboration With Roche
DJ
07:44aBICYCLE THERAPEUTICS : in Collaboration Agreement with Genentech
DJ
More sector news : Pharmaceuticals - NEC
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 101,00  $
Last Close Price 93,14  $
Spread / Highest target 39,6%
Spread / Average Target 8,44%
Spread / Lowest Target -9,81%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.5.20%137 769
JOHNSON & JOHNSON2.78%384 432
ROCHE HOLDING AG6.61%290 942
NOVARTIS-0.66%211 608
MERCK AND COMPANY-10.58%207 065
PFIZER-8.83%191 868